Opinion
Volume 10:05, 2024

Immunochemistry & Immunopathology

ISSN: 2469-9756 Open Access

Targeted Drug Delivery in Periorbital Non-melanocytic Skin Malignancies

Garbe Meyer*

Department of Tumor Immunology, University of Rwanda, Kigali, Rwanda

Introduction

Skin cancers represent one of the most prevalent forms of cancer worldwide, with Non-Melanocytic Skin Cancers (NMSCs), including Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC), accounting for the majority of cases. Periorbital NMSCs refer to malignancies that occur around the eyes, affecting the delicate skin surrounding the orbit. These tumors, while often localized and manageable in early stages, present significant challenges due to their location near critical structures, such as the eyelids, cornea, and optic nerve. Traditional treatment options, including surgical excision, radiation therapy, and topical treatments, have been successful but are not without limitations. In particular, these methods can sometimes lead to poor cosmetic outcomes, complications related to tissue damage, and recurrence, especially when tumors are situated in hard-to-reach or sensitive areas like the periorbital region [1].

As the field of oncology evolves, innovative approaches to treating these cancers have emerged, one of the most promising being Targeted Drug Delivery (TDD). Targeted Drug Delivery Systems (TDDS) aim to deliver therapeutic agents directly to cancer cells while minimizing systemic toxicity and damage to healthy tissues. This technique is particularly advantageous in treating periorbital NMSCs, where precision and sparing of surrounding healthy tissue are critical. By utilizing targeted therapies, healthcare providers can enhance treatment efficacy while reducing side effects, improving patient outcomes, and preserving quality of life [2].

Description

Non-melanocytic skin cancers, comprising mainly Basal Cell Carcinoma (BCC) and squamous cell carcinoma (SCC), are the most common skin cancers. The majority of NMSCs arise from keratinocytes, and their incidence is increasing, particularly in fair-skinned populations. These tumors are often attributed to Ultraviolet (UV) radiation exposure, which induces mutations in the DNA of skin cells. BCC is the most common type of NMSC and is characterized by slow growth and a tendency to remain localized. However, BCC can be aggressive and difficult to treat when it occurs in anatomically complex or sensitive areas, such as the periorbital region. It can invade local structures, including the eyelid, conjunctiva, lacrimal glands, and even the orbit itself, necessitating careful management. SCC is less common than BCC but has a higher potential for metastasis, particularly when located in high-risk areas such as the periorbital region. SCC in these areas requires aggressive treatment due to the risk of regional spread and distant metastasis. The proximity of these tumors to vital structures, such as the eye and the optic nerve, underscores the importance of preserving functionality and cosmetic appearance while treating these cancers [3].

Traditional treatments for periorbital NMSCs typically involve a combination of surgical excision, radiation therapy, and topical treatments such as imiquimod or 5-fluorouracil (5-FU). Each of these modalities has limitations, especially when it comes to the periorbital region. The gold standard for treating NMSCs in the periorbital area, surgical excision offers the potential for complete removal of the tumor. However, it carries risks, including damage to adjacent structures such as the eyelid, lacrimal glands, or ocular tissues. The need for careful cosmetic reconstruction post-surgery is a critical consideration in these cases. Radiation is often used in cases where surgery is not feasible, or as an adjunct to surgery in high-risk cases. While effective at targeting tumors, radiation can lead to long-term side effects, including skin damage, dryness, and in rare cases, secondary cancers. The periorbital region is particularly sensitive to radiation, making it important to carefully plan the dose and distribution to avoid harming nearby structures. Agents like 5-FU and imiquimod are used for superficial skin cancers, often in cases of actinic keratosis or small, non-invasive BCCs. While these treatments are less invasive than surgery or radiation, they can be less effective for deeper or more extensive tumors, and their use is limited to specific types of NMSCs [4].

Targeted Drug Delivery (TDD) is an advanced therapeutic approach that aims to increase the concentration of a drug in specific tissues while minimizing exposure to healthy tissues. This system utilizes various strategies to direct therapeutic agents to the site of action, improving the specificity and efficacy of treatment. Nanoparticles and nanocarriers are small-sized carriers, typically ranging from 10 to 1000 nanometers, that can encapsulate drugs and deliver them directly to cancer cells. Nanoparticles can be engineered to target specific receptors or antigens present on tumor cells, improving the accumulation of the drug at the tumor site. Liposomes, dendrimers, and polymeric nanoparticles are examples of carriers used in drug delivery systems. Receptor-mediated targeting approach involves attaching drugs to molecules that bind specifically to receptors overexpressed on cancer cells. These receptors are often involved in cell proliferation, survival, and other cancer-related processes. For example, targeting epidermal growth factor receptors (EGFR), which are overexpressed in many types of skin cancer, can increase the delivery of chemotherapy agents to tumor cells. Convection-Enhanced Delivery (CED), a drug is delivered directly into the tumor tissue through a catheter, with the help of a pressure gradient to force the drug into the tumor. This technique can be useful for deep-seated tumors and provides a high local concentration of the drug with reduced systemic exposure [5].

Conclusion

Targeted drug delivery represents a promising and innovative approach to the treatment of periorbital non-melanocytic skin malignancies. By improving the precision and local efficacy of therapeutic agents, targeted delivery systems have the potential to reduce systemic toxicity, enhance treatment outcomes, and preserve the delicate structures of the periorbital region. While challenges remain, including the anatomical complexity of the area and potential side effects, ongoing research and technological advancements continue to drive the development of more effective and less invasive therapies. The future of targeted drug delivery for periorbital NMSCs looks promising, with new drug formulations, advanced delivery technologies, and personalized treatment approaches set to redefine the management of these challenging tumors. As

***Address for Correspondence:** Garbe Meyer, Department of Tumor Immunology, University of Rwanda, Kigali, Rwanda, E-mail: garbe.meyer@gmail.com*

Received: 04 October, 2024, Manuscript No. icoa-24-152610; **Editor assigned:** 07 October, 2024, PreQC No. P-152610; **Reviewed:** 17 October, 2024, QC No. Q-152610, **Revised:** 22 October, 2024, Manuscript No. R-152610; **Published:** 29 October, 2024, DOI: 10.37421/2469-9756.2024.10.261

these innovations are integrated into clinical practice, patients with periorbital NMSCs may benefit from more effective treatments with fewer side effects, ultimately improving both survival rates and quality of life.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Shi, Yang, Roy van der Meel, Xiaoyuan Chen and Twan Lammers. "The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy." *Theranostics* 10 (2020): 7921.
2. Liu, Yun, Guangze Yang, Song Jin and Letao Xu, et al. "Development of high-drug-loading nanoparticles." *Chem Plus Chem* 85 (2020): 2143-2157.
3. Patil, Siddhesh D., David G. Rhodes and Diane J. Burgess. "DNA-based therapeutics and DNA delivery systems: A comprehensive review." *The AAPS J* 7 (2005): E61-E77.
4. Abou-el-Enein, Mohamed, Magdi Elsallab, Steven A. Feldman and Andrew D. Fesnak, et al. "Scalable manufacturing of CAR T cells for cancer immunotherapy." *Blood Canc Discover* (2021): 408-422.
5. Unsworth, Shelby P., Christina F. Tingle, Curtis J. Heisel and Emily A. Eton, et al. "Analysis of residual disease in periocular basal cell carcinoma following hedgehog pathway inhibition: Follow up to the VISORB trial." *Plos one* 17 (2022): e0265212.

How to cite this article: Meyer, Garbe. "Targeted Drug Delivery in Periorbital Non-melanocytic Skin Malignancies." *Immunochem Immunopathol* 10 (2024): 261.